Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization vs Cryotherapy

This study is designed to compare the efficacy of topical ingenol mebutate (150 mcg/g once daily on a selected facial or scalp target area of 25 cm2, for 3 consecutive days) with cryosurgery (applied for a freeze time of 5 seconds, on each lesion included in an area of 25 cm2 on face or scalp)

This is a national, post-marketing (phase 4), on label, interventional, randomized trial.

Subjects will attend a screening visit where they will be assessed for eligibility.

Two areas of treatment in the same patient have to be identified (e.g. scalp and cheek or two different part of the balding scalp), than these two areas will be randomized in a 2:1 ratio: one will be treated with cryosurgery and the other one with Picato Gel.

The cryosurgery will be performed in the same day during the visit (1 application for a freeze time of 5 seconds, on each lesion included in an area of 25 cm2 on face or scalp) Picato gel 150 mcg will be applied at home by the patient, according to current indication (RCP: 3 consecutive days for a total of three application in an area of 25 cm2) Subjects will be followed for 24 weeks (about 6 months) after the cryosurgery application (Visit 1).

Adverse events and patient compliance will be recorded 7 days after cryosurgery application and 5 days after first Picato gel application (Visit 2). The number of AKs present within the treatment areas will be counted at Visit 1 (Baseline AK count) and at Visits 3 - 4 (AKcount). The data obtained will provide information on the effect of Picato gel versus Cryosurgery on recurrence rate of AKs.

Furthermore, the trial will also provide data on the effect of Picato gel versus Cryosurgery on the appearance rate of new AKs.

The final results for all subjects will be included in a Final Clinical Study Report in the original submission. This includes final results for all primary and secondary endpoints as well as 6-month recurrence and Adverse Event data.

Inclusion criteria

A patient will be enrolled if he/she meets all of the following inclusion criteria:

• Current diagnosis of AK, with ≥2 lesions of grade I and/or II located in two different anatomical districts (within a contiguous 25 cm2 area on the face, scalp or forehead);
• Male ≥ 18 years of age or Female > 60 years of age;
• Skin type I or II according to Fitzpatrick;
• Patient has confirmed his/her willingness to participate in this study after being informed of all aspects of the study that are relevant to his/her decision to participate, by signing and dating the approved informed consent form, according to ICH and local laws.

The 25 cm2 contiguous treatment areas could be of any shape, e.g. 5 cm x 5 cm, 2 cm x 12.5 cm, 3 cm x 8.3 cm.

Exclusion criteria

A patient will be excluded if he/she meets any of the following exclusion criteria:

• Has received any therapy for AK within the past 3 months
• Has AK of grade III
• Has currently a skin cancer or shows an early stage of skin cancer;
• Has another skin disease that requires treatment with other medications in the AK area or in distance of 3 cm;
• Use of cosmetic or therapeutic products and procedures which could interfere with assessments of the treatment area;
• Immunosuppressive therapies or current treatment for cancer;
• Clinically unstable medical condition;
• High risk group for HIV infection or presentation of other infectious diseases (hepatitis A virus , hepatitis B virus , hepatitis C virus , Tuberculosis, etc);
• Allergies to the tested gel (ingenol mebutate and eccipients);
• Pregnancy and breastfeeding (see inclusion criteria);
• Psychiatric disease that may interfere with follow-up of study procedures;
• Participation in other clinical trials up to 30 days prior to day 1 of the study;
• Patient is, for any reason, considered by the investigator to be an unsuitable candidate for the study.